Sostres C, Marcén B, Laredo V, et al. - Among 871 individuals (mean age 78.9 ± 8.6 years) treated with antiplatelet or anticoagulant agents who developed major gastrointestinal bleeding, researchers used Cox proportional hazards models to determine the risk/rates of rebleeding, vascular events and death. The results obtained from the observational cohort study suggest an association of resumption of anticoagulant or antiplatelet therapy after a gastrointestinal bleeding event with a lower risk of vascular events and death and a higher rebleeding risk. The advantages of anticoagulant/antiplatelet therapy's early reinstitution outweigh the gastrointestinal-related dangers. In patients taking anticoagulant agents, the risk of rebleeding is especially present.